TYRA Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines for targeted oncology and genetically defined conditions, leveraging Fibroblast Growth Factor Receptor (FGFR) biology. The company's proprietary SNP platform enables rapid and precise drug design through iterative molecular SNPshots. The lead program, oral dabogratinib (formerly TYRA-300), is currently in three Phase 2 trials: SURF303 for low-grade upper tract urothelial carcinoma (LG-UTUC), SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC), and BEACH301 for achondroplasia (ACH) in children. Initial clinical proof-of-concept results for oral dabogratinib in the SURF301 study (metastatic urothelial carcinoma) demonstrated encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2and FGFR1-associated toxicities. TYRA-430, an FGFR4/3 biased inhibitor for FGF19+ hepatocellular carcinoma (HCC), commenced its global Phase 1 clinical trial (SURF431) in April 2025. TYRA-200, an FGFR1/2/3 inhibitor designed to address acquired resistant mutations in FGFR2-driven intrahepatic cholangiocarcinoma (ICC), commenced its global Phase 1 clinical trial (SURF201) in December 2023. The net loss for the year ended December 31, 2025, was $119.9 million, an increase from $86.5 million in 2024. As of December 31, 2025, the company had an accumulated deficit of $371.3 million. Cash, cash equivalents, and marketable securities totaled $256.0 million as of December 31, 2025, which is expected to fund operations through at least 2027. Oral dabogratinib received Orphan Drug Designation (July 2023) and Rare Pediatric Disease Designation (January 2024) from the FDA for the treatment of ACH.